Last reviewed · How we verify
NCT06096896
The Efficacy and Safety of EOB-MRI Guided Microwave Ablation for Early HCC: A Multicenter, Prospective, Observational Study
trial testing MWA in Early Hepatocellular Carcinoma in 334 participants. Participants enrolled and being followed up; not accepting new ones.
30 September 2025
Quick facts
| Lead sponsor | Shandong Provincial Hospital |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 334 |
| Start date | 30 August 2023 |
| Primary completion | 30 September 2025 |
| Estimated completion | 30 September 2030 |
| Sites | 1 location across China |
Drugs / interventions tested
- MWA
Conditions studied
- Early Hepatocellular Carcinoma — all drugs for Early Hepatocellular Carcinoma →
Sponsor
Shandong Provincial Hospital
Who can join
18 and older, any sex, with Early Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
HCC is one of most common causes of cancer-related death in the world due to lately diagnosis by typical hallmarks which rely on completed arterialization. So it is important to earlier diagnose and treat hypovascular early HCC(eHCC). The aim of this study is to evaluate the efficacy and safety of microwave ablation for early HCC, also to explore the feasibility of EOB-MRI (Gd-EOB-DTPA enhanced MRI) guided ablation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06096896
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of MWA
Trials testing the same drug.
- NCT06929390 — Comparing BTVA and MWA in COPD With Early Lung Cancer: Efficacy and Safety · NA · not yet recruiting
- NCT03654131 — Microwave Ablation Versus Stereotactic Body Radiotherapy for Colorectal Liver Metastases in Oligometastatic Disease: a P · Phase 2 · active not recruiting
- NCT03277716 — Microwave Ablation Combined With TACE in the Treatment of Unresectable Huge Hepatocellular Carcinoma Huge · NA · unknown
Other Shandong Provincial Hospital trials
Trials by the same sponsor.
- NCT07333287 — A Multicenter Single-arm Prospective Clinical Study on First-line Treatment of Pancreatic Cancer Liver Metastases With A · Phase 2 · not yet recruiting
- NCT07180342 — An Empirical Study on the Mechanisms of Biopsychosocial Functional Improvement in Patients With Major Depressive Disorde · NA · recruiting
- NCT07284992 — SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC · Phase 2 · recruiting
- NCT06908382 — Neoadjuvant QL1706 Therapy for ESCC · Phase 2 · recruiting
- NCT06829797 — A Multicenter Randomized Controlled Phase II Trial of Iparomlimab and Tuvonralimab (QL1706) Combined with SOX Chemothera · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06096896 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shandong Provincial Hospital
- Last refreshed: 24 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06096896.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing